Journal Article
. 2016 Dec;3(3).
doi: 10.1001/jamaoncol.2016.5652.

Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences

Allison W Kurian 1 Christopher R Friese 2 Irina Bondarenko 3 Reshma Jagsi 4 Yun Li 3 Ann S Hamilton 5 Kevin C Ward 6 Steven J Katz 7 
Affiliations
  • PMID: 28033448
  •     46 References
  •     9 citations

Abstract

Importance: Advances in the evaluation and treatment of breast cancer have made the clinical decision-making context much more complex. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use.

Objective: To investigate the patterns and correlates of second opinion use and the effect on chemotherapy decisions.

Design, Setting, And Participants: A total of 1901 women newly diagnosed with stages 0 to II breast cancer between July 2013 and September 2014 (response rate, 71.0%) were accrued through 2 population-based Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles County, California) and surveyed about their experiences with medical oncologists, decision making, and chemotherapy use.

Main Outcomes And Measures: Factors associated with second opinion use were evaluated using logistic regression. Also assessed was the association between second opinion and chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second opinion. Multiple imputation and weighting were used to account for missing data.

Results: A total of 1901 patients with stage I to II breast cancer (mean [SD] age, 61.6 [11.0] years; 1071 [56.3%] non-Hispanic white) saw any medical oncologist. Analysis of multiply imputed, weighted data (mean n = 1866) showed that 168 (9.8%) (SE, 0.74%) received a second opinion and 54 (3.2%) (SE, 0.47%) received chemotherapy from the second oncologist. Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P = .29). Predictors of second opinion use included college education vs less education (odds ratio [OR], 1.85; 95% CI, 1.24-2.75), frequent use of internet-based support groups (OR, 2.15; 95% CI, 1.12-4.11), an intermediate result on the 21-gene recurrence score assay (OR, 1.85; 95% CI, 1.11-3.09), and a variant of uncertain significance on hereditary cancer genetic testing (OR, 3.24; 95% CI, 1.09-9.59). After controlling for patient and tumor characteristics, second opinion use was not associated with chemotherapy receipt (OR, 1.04; 95% CI, 0.71-1.52).

Conclusions And Relevance: Second opinion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfaction regardless of second opinion use suggests little unmet demand. Along with educational level and use of internet support groups, uncertain results on genomic testing predicted second opinion use. Patient demand for second opinions may increase as more complex genomic tests are disseminated.

Diagnostic concordance among pathologists interpreting breast biopsy specimens.
Joann G Elmore, Gary M Longton, +9 authors, Donald L Weaver.
JAMA, 2015 Mar 18; 313(11). PMID: 25781441    Free PMC article.
Highly Cited.
American Society of Clinical Oncology 2013 top five list in oncology.
Lowell E Schnipper, Gary H Lyman, +4 authors, Richard L Schilsky.
J Clin Oncol, 2013 Oct 31; 31(34). PMID: 24170249
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +3 authors, Lesley H Curtis.
JAMA Oncol, 2015 Jul 17; 1(2). PMID: 26181015
Improved Breast Cancer Care Quality Metrics After Implementation of a Standardized Tumor Board Documentation Template.
Daniel J Farrugia, Trevan D Fischer, +2 authors, Christiana M Shaw.
J Oncol Pract, 2015 Sep 19; 11(5). PMID: 26384016
Patterns and correlates of patient referral to surgeons for treatment of breast cancer.
Steven J Katz, Timothy P Hofer, +6 authors, Monica Morrow.
J Clin Oncol, 2007 Jan 20; 25(3). PMID: 17235044
Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women.
Eileen M Kesson, Gwen M Allardice, +2 authors, David S Morrison.
BMJ, 2012 Apr 28; 344. PMID: 22539013    Free PMC article.
Highly Cited.
Usefulness of Multigene Testing: Catching the Train That's Left the Station.
Elizabeth M Swisher.
JAMA Oncol, 2015 Aug 14; 1(7). PMID: 26270409
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, +17 authors, Pinuccia Valagussa.
Lancet Oncol, 2011 Dec 14; 13(1). PMID: 22153890
Highly Cited.
How can we best respect patient autonomy in breast cancer treatment decisions?
Kathryn A Martinez, Allison W Kurian, Sarah T Hawley, Reshma Jagsi.
Breast Cancer Manag, 2015 Mar 04; 4(1). PMID: 25733982    Free PMC article.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Physicians' attitudes about multiplex tumor genomic testing.
Stacy W Gray, Katherine Hicks-Courant, +2 authors, Jane C Weeks.
J Clin Oncol, 2014 Mar 26; 32(13). PMID: 24663044    Free PMC article.
Highly Cited.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2016 Mar 10; 14(3). PMID: 26957618
Highly Cited.
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.
Diego Munoz, Aimee M Near, +16 authors, Sylvia K Plevritis.
J Natl Cancer Inst, 2014 Sep 27; 106(11). PMID: 25255803    Free PMC article.
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.
Jared K Lunceford, Marie Davidian.
Stat Med, 2004 Sep 08; 23(19). PMID: 15351954
Highly Cited.
Social and Clinical Determinants of Contralateral Prophylactic Mastectomy.
Sarah T Hawley, Reshma Jagsi, +4 authors, Steven J Katz.
JAMA Surg, 2014 May 23; 149(6). PMID: 24849045    Free PMC article.
Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.
Reshma Jagsi, Kent A Griffith, +5 authors, Sarah T Hawley.
J Clin Oncol, 2015 Apr 08; 33(14). PMID: 25847940    Free PMC article.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Paul E Goss, James N Ingle, +17 authors, Wendy R Parulekar.
N Engl J Med, 2016 Jun 07; 375(3). PMID: 27264120    Free PMC article.
Highly Cited.
Breast cancer treatment decision-making: are we asking too much of patients?
Jennifer C Livaudais, Rebeca Franco, Kezhen Fei, Nina A Bickell.
J Gen Intern Med, 2012 Dec 12; 28(5). PMID: 23229908    Free PMC article.
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
Michael J Hall, Julia E Reid, +7 authors, Walter W Noll.
Cancer, 2009 Feb 26; 115(10). PMID: 19241424    Free PMC article.
Highly Cited.
Breast Imaging Second Opinions Impact Surgical Management.
Tara Lynn Spivey, Kjirsten Ayn Carlson, +3 authors, Andrea Madrigrano.
Ann Surg Oncol, 2015 Jan 23; 22(7). PMID: 25608767
Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information.
Allison W Kurian, Antonis C Antoniou, Susan M Domchek.
Am Soc Clin Oncol Educ Book, 2016 Jun 02; 35. PMID: 27249685
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
A Schneeweiss, S Chia, +10 authors, J Cortés.
Ann Oncol, 2013 May 25; 24(9). PMID: 23704196
Highly Cited.
Second opinion in breast pathology: policy, practice and perception.
Berta M Geller, Heidi D Nelson, +6 authors, Joann G Elmore.
J Clin Pathol, 2014 Jul 24; 67(11). PMID: 25053542    Free PMC article.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Stephen Jones, Frankie Ann Holmes, +17 authors, Michael A Savin.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204201
Highly Cited.
Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.
Kara N Maxwell, Bradley Wubbenhorst, +11 authors, Katherine L Nathanson.
Genet Med, 2014 Dec 17; 17(8). PMID: 25503501    Free PMC article.
Latinas and breast cancer outcomes: population-based sampling, ethnic identity, and acculturation assessment.
Ann S Hamilton, Timothy P Hofer, +5 authors, Steven J Katz.
Cancer Epidemiol Biomarkers Prev, 2009 Jun 25; 18(7). PMID: 19549806    Free PMC article.
Surgeon recommendations and receipt of mastectomy for treatment of breast cancer.
Monica Morrow, Reshma Jagsi, +5 authors, Steven J Katz.
JAMA, 2009 Oct 15; 302(14). PMID: 19826024    Free PMC article.
Highly Cited.
Multigene Panel Testing in Oncology Practice: How Should We Respond?
Allison W Kurian, James M Ford.
JAMA Oncol, 2015 Jul 17; 1(3). PMID: 26181167
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Effect of screening and adjuvant therapy on mortality from breast cancer.
Donald A Berry, Kathleen A Cronin, +8 authors, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.
N Engl J Med, 2005 Oct 28; 353(17). PMID: 16251534
Highly Cited.
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Manfred Kaufmann, Gunter von Minckwitz, +16 authors, Lajos Pusztai.
Ann Surg Oncol, 2011 Dec 24; 19(5). PMID: 22193884
Highly Cited.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board.
Erika A Newman, Amy B Guest, +9 authors, Michael S Sabel.
Cancer, 2006 Sep 26; 107(10). PMID: 16998942
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer.
Tuya Pal, Deborah Cragun, +6 authors, Susan T Vadaparampil.
Genet Test Mol Biomarkers, 2013 Mar 02; 17(5). PMID: 23448386    Free PMC article.
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.
Allison W Kurian, Emily E Hare, +9 authors, James M Ford.
J Clin Oncol, 2014 Apr 16; 32(19). PMID: 24733792    Free PMC article.
Highly Cited.
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Andrea Desmond, Allison W Kurian, +10 authors, Leif W Ellisen.
JAMA Oncol, 2015 Aug 14; 1(7). PMID: 26270727
Highly Cited.
Motivational predictors of weight loss and weight-loss maintenance.
G C Williams, V M Grow, +2 authors, E L Deci.
J Pers Soc Psychol, 1996 Jan 01; 70(1). PMID: 8558405
Highly Cited.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Angela DeMichele, Douglas Yee, +39 authors, Laura J Esserman.
Clin Cancer Res, 2015 Feb 26; 21(13). PMID: 25712686    Free PMC article.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Decline in the use of anthracyclines for breast cancer.
Sharon H Giordano, Yu-Li Lin, +2 authors, James S Goodwin.
J Clin Oncol, 2012 May 23; 30(18). PMID: 22614988    Free PMC article.
Breast pathology second review identifies clinically significant discrepancies in over 10% of patients.
Laila Khazai, Lavinia P Middleton, +2 authors, Aysegul A Sahin.
J Surg Oncol, 2014 Oct 03; 111(2). PMID: 25273328
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
Allison W Kurian, Yun Li, +6 authors, Steven J Katz.
J Clin Oncol, 2017 Apr 14; 35(20). PMID: 28402748    Free PMC article.
Highly Cited.
Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?
Steven J Katz, Sarah T Hawley, +4 authors, Allison W Kurian.
Breast Cancer Res Treat, 2017 Jul 10; 165(3). PMID: 28689364    Free PMC article.
Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, +7 authors, Steven J Katz.
J Natl Cancer Inst, 2017 Dec 14; 110(5). PMID: 29237009    Free PMC article.
Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Allison W Kurian, Kevin C Ward, +8 authors, Steven J Katz.
JAMA Oncol, 2018 May 26; 4(8). PMID: 29801090    Free PMC article.
Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.
Steven J Katz, Irina Bondarenko, +4 authors, Timothy P Hofer.
JAMA Surg, 2018 Jul 05; 153(10). PMID: 29971344    Free PMC article.
Impact of Second Opinions in Breast Cancer Diagnostics and Treatment: A Retrospective Analysis.
E Heeg, Y A Civil, +5 authors, M T F D Vrancken Peeters.
Ann Surg Oncol, 2019 Oct 13; 26(13). PMID: 31605324    Free PMC article.
Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
Rachid Karam, Blair Conner, +22 authors, Elizabeth Chao.
JAMA Netw Open, 2019 Oct 24; 2(10). PMID: 31642931    Free PMC article.
Second opinions in medical oncology.
Ian Olver, Mariko Carey, +3 authors, Rob Sanson-Fisher.
BMC Palliat Care, 2020 Jul 23; 19(1). PMID: 32693836    Free PMC article.
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
N Jewel Samadder, Douglas Riegert-Johnson, +25 authors, A Keith Stewart.
JAMA Oncol, 2020 Oct 31; 7(2). PMID: 33126242    Free PMC article.